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Pharma on the Hot Seat 
 
Nicole Huberfeld∗ 
 
ABSTRACT:  The pharmaceutical industry has been receiving greater scrutiny lately due 
in large part to the many public and private legal enforcement actions taken against 
pharmaceutical manufacturers. These enforcement actions, along with legal 
developments such as the OIG Compliance Guidance for Pharmaceutical Manufacturers, 
the Sarbanes-Oxley Act’s statutory guidelines for public corporations, the HIPAA 
privacy regulations, and the Medicare Modernization Act, have the potential to encourage 
the pharmaceutical industry to self-regulate beyond the bounds currently required by the 
law. After a brief overview of enforcement actions and compliance programs directed 
toward the pharmaceutical industry, this Article reviews a similar situation the hospital 
industry faced when Medicare promulgated major reimbursement modifications. The 
Article proposes that the pharmaceutical industry, in the face of such intense scrutiny and 
uncertainty, should implement more rigorous self-regulation. Without more stringent 
self-regulation, this intense interest in the pharmaceutical industry may result in a 
regulatory push that establishes unanticipated and cumbersome measures for the industry. 
 
Though headlines like “Gimme an Rx! Cheerleaders Pep Up Drug Sales” do not 
necessarily reflect accurately the pharmaceutical industry, its culture, or its practices, they 
do demonstrate that the industry (and its associates, medical devices and biologics) has 
drawn high profile scrutiny.1 This intense interest issues from multiple sources; by 
example, criminal and civil investigations and settlements pursued by the Department of 
Justice (DOJ) and the Department of Health and Human Services (DHHS) have become 
headline-grabbers.2 
 
Other legal developments also have focused greater attention on the pharmaceutical 
industry. Among the most notable are the Office of the Inspector General for the 
Department of Health and Human Services’ (OIG) Compliance Guidance for 
Pharmaceutical Manufacturers and its subsequent attention to the industry;3 the Sarbanes-
Oxley Act’s statutory guidance for public corporations and the increased importance of 
corporate best practices; the privacy regulations of the Health Insurance Portability and 
                                                 
∗ Assistant Professor, University of Kentucky College of Law. I would like to thank Tim Greaney and 
Nicolas Terry for their helpful comments and Maria Gall for her research assistance. Thanks DT. 
1 See Stephanie Saul, Gimme an Rx! Cheerleaders Pep Up Drug Sales, N.Y. TIMES, Nov. 28, 2005, at A1; 
see also Reed Abelson, Whistle-Blower Suit Says Device Maker Generously Rewards Doctors, N.Y. 
TIMES, Jan. 24, 2006, at C1 (discussing the whistleblower action against Medtronic and noting the general 
interest in the financial transactions occurring in the medical device industry). 
2 See Reimbursement and Access to Prescription Drugs Under Medicare Part B, 107th Cong. 88–89 (2002) 
(statement of Janet Rehnquist, Inspector Gen., U.S. Dep’t of Health & Human Servs. (DHHS)), available 
at finance.senate.gov/hear-ings/81823.pdf (last visited May. 24, 2007); Press Release, Off. of Inspector 
Gen. (OIG), DHHS, OIG Report Highlights Progress Against Waste, Abuse, and Fraud (Dec. 9, 2004), 
available at oig.hhs.gov/publications/docs/press/2004/120904Release.pdf (last visited May. 24, 2007). 
3 See, e.g., OIG, DHHS, FISCAL YEAR 2005 WORK PLAN - PUBLIC HEALTH AGENCIES 5 (2005), 
available at oig.hhs.gov/reading/workplan/2005/2005WPPHAs.pdf (last visited May. 24, 2007). 
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Accountability Act of 1996 (HIPAA); and the Medicare Prescription Drug, Improvement 
and Modernization Act of 2003 (MMA) with the Medicare Part D drug benefit.4 
 
The impact of these disparate developments, combined, indicates a need for proactive 
vigilance through compliance programs that surpass the “letter” of current law, a lesson 
that may be learned from the experiences of others in the health-care industry. After 
considering the above-mentioned legal developments, this Article will briefly review the 
attention that the hospital industry sustained both before and after major reimbursement 
modifications were imposed by Medicare. The hospital experience suggests that players 
in the healthcare industry, when subject to uncertainty combined with intense scrutiny, 
may need to self-regulate to a degree that exceeds apparent legal requirements. 
 
I. High Profile Settlements 
 
A recent OIG Semi-Annual Report illustrates the attention being paid to the 
pharmaceutical industry.5 In that document, the OIG identified multimillion-dollar 
recoveries resulting from investigating and settling with the pharmaceutical industry (i.e., 
recoveries not involving judicial conclusions or awards) and described the new 
responsibilities that result from the Medicare drug benefit.6 Among the pharmaceutical 
industry settlements listed are a $345.5 million settlement with Schering-Plough, a $5.9 
million settlement with PharMerica, and a settlement with a stand-alone pharmacy for 
$476,000.7 After this Semi-Annual Report was published, King Pharmaceuticals agreed 
to pay $124 million and to enter into a five-year corporate integrity agreement (CIA) to 
settle allegations of fraud related to rebates required by federal Medicaid rules.8 
                                                 
4 The spotlight also is intensified by Senator Chuck Grassley (R-IA), former Chair-man of the Senate 
Finance Committee (and self-created Healthcare Fraud Czar), who acts as a “whistleblower” on the 
“management practices of the IRS, FBI, Department of Homeland Security and the Centers for Medicare 
and Medic-aid Services” and who lately has commented with vigor on the FDA and the pharmaceutical 
industry. See U.S. Senator Chuck Grassley, Biography, at tinyurl.com/l6k5a (last visited May 24, 2007); 
Press Release, Gov’t Accountability Project, Senator Grassley Investigates Charges of FDA and Wyeth 
Misconduct (Nov. 18, 2005), available at www.whistleblower.org/content/press_detail.cfm?press_id=291 
(last visited May 24, 2007); Kaiser Family Foundation, Senators Introduce Bill to Establish New FDA 
Prescription Drug Safety Office, DAILY HEALTH POL’Y REP., Apr. 28, 2005, available at 
tinyurl.com/gcgf3 (last visited  May 24, 2007). 
5 See OIG, DHHS, SEMIANNUAL REP. at 13, 15 (Oct. – Mar. 2005), available at 
oig.hhs.gov/publications/docs/semiannual/2005/SemiannualSpring05.pdf.  The most recent Semiannual 
Report continues the trend of scrutiny, reporting investigations of Average Manufacturer Price, 340B drug 
pricing, and Medicare Part B drug pricing in addition to the highly publicized settlement with the 
prescription benefit manager AdvancePCS (for $137.5 million).  See OIG, DHHS, SEMIANNUAL REP. at 
3-5, 22 (April - Sep. 2006), available at oig.hhs.gov/publica-
tions/docs/semiannual/2006/Semiannual%20Final%20FY%202006.pdf. 
6 See OIG, DHHS, SEMIANNUAL REP. (Oct. - March 2005) at 11 – 14. 
7 Id. at 13, 15. 
8 Press Release, U.S. Attorney E. Dist. of Pa., U.S. Dep’t of Justice (DOJ), U.S. Reaches $124 Million 
Settlement with Drug Maker (Nov. 1, 2005), available at 
www.usdoj.gov/usao/pae/News/Pr/2005/nov/Kingpressrelease.pdf (last visited May. 24, 2007); see 
Corporate Integrity Agreement Between the Office of Inspector General of the Department of Health and 
Human Services and King Pharmaceuticals, Inc., Oct. 31, 2005, at 1, available at 
oig.hhs.gov/fraud/cia/agreements/KingPharmaceuticalsCIA.pdf (last visited May 24, 2007). 
Journal of Health Law Vol. 40 No. 2 
 
Such multimillion-dollar payments are a continuation of a re-cent string of highly 
publicized settlements with the pharmaceutical industry.9 The prominence of these 
federal investigations was launched with the TAP Pharmaceutical Products, Inc. (TAP) 
global settlement of 2001, which cost the manufacturer of the prostate cancer drug 
Lupron $875 million in criminal and civil penalties.10 TAP was the federal government’s 
first “big win” against a major player in the pharmaceutical industry (and, as is common 
practice with government settlements, created a source of funding for ongoing efforts to 
investigate and prosecute pharmaceutical companies).11 The prosecution’s theory in the 
TAP case was that the company had guided physicians to receive reimbursement for 
samples of drugs; had “marketed the spread” between the cost to physicians of 
purchasing Lupron and the reimbursement available from the federal government due to 
the average wholesale price (AWP) of Lupron, arguably facilitating over-reimbursement 
by its buyers; and had given kickbacks to physicians for prescribing certain TAP 
products.12 The sales practices described in the complaint were not unique to TAP, but a 
TAP sales representative had attempted to pay a kickback to a doctor, who then reported 
the bribe to the federal government, thus bringing TAP’s business practices to the 
attention of federal prosecutors.13 TAP put the pharmaceutical industry on the fraud 
prosecution map.14 The settlement effectively posted a notice to the largest corporations 
in the healthcare industry that the DOJ, the Centers for Medicare & Medicaid Services 
(CMS), and the OIG were turning their attention to the pharmaceutical industry, which 
largely had been left alone during the years of increasing healthcare fraud prosecutions.15 
                                                 
9 Stephanie Greene, False Claims Act Liability for Off-Label Promotion of Pharmaceutical Products, 110 
PENN ST. L. REV. 41, 42 & n.9 (2005) (noting recent government actions and outcomes against the 
pharmaceutical industry). 
10 See OIG, DHHS, SEMIANNUAL REP. at 18 (Oct. – Mar. 2002), available at 
oig.hhs.gov/reading/semiannual/2002/Spring%20SemiAnnual%202002.pdf (last visited May 24, 2007). 
11 See GlaxoSmithKline Settles Fraud Allegations Under False Claims Act, INSIDE CMS, Oct. 6, 2005, at 
20. Cf. Pamela H. Bucy, The Path from Regulator to Hunter: The Exercise of Prosecutorial Discretion in 
the Investigation of Physicians at Teaching Hospitals, 44 ST. LOUIS U. L.J. 3, 15 (2000) (explaining the 
self-funding mechanism for prosecutions under HIPAA in the context of teaching hospital prosecutions, 
called PATH audits); Robert Salcido, The Government’s Increasing Use of the False Claims Act Against 
the Health Care Industry, 24 J. LEGAL MED. 457, 463 & n.35 (2003) (describing how certain provisions 
of HIPAA facilitated use of False Claims Act recoveries for additional prosecutions). 
12 Press Release, DOJ, TAP Pharmaceutical Products Inc. and Seven Others Charged with Health Care 
Crimes; Company Agrees to Pay $875 Million to Settle Charges (Oct. 3, 2001) [hereinafter Press Release, 
TAP], available at www.usdoj.gov/opa/pr/2001/October/513civ.htm (last visited May 24, 2007); see OIG, 
DHHS, Civil Monetary Penalties: Kickback and Physician Self-Referral (Jan. 13, 2003), available at 
oig.hhs.gov/fraud/enforcement/administrative/cmp/cmpitems.html#3 (last visited May 24, 2007) (noting 
that physicians who received kickbacks from TAP were also charged under the Anti-kickback Statute). 
13 Press Release, TAP, supra note 12. 
14 See Pamela H. Bucy, Games and Stories: Game Theory and the Civil False Claims Act, 31 FLA. ST. U. 
L. REV. 603, 611 & n.43 (2004) (citing TAP as one example of the grandiosity of False Claims Act 
settlements); Joan H. Krause, Regulating, Guiding, and Enforcing Health Care Fraud, 60 N.Y.U. ANN. 
SURV. AM. L. 241, 267 – 68 (2004) (noting that the TAP settlement highlighted the potential for abusing 
average wholesale price); Sheryl Calabro, Note, Breaking the Shield of the Learned Intermediary Doctrine: 
Placing the Blame Where it Belongs, 25 CARDOZO L. REV. 2241, 2265 (2004) (noting that TAP was the 
largest healthcare fraud settlement in history when it was announced by the Department of Justice). 
15 See Abelson, supra note 1 (reporting that eight of the major medical device manufacturers were 
subpoenaed in 2005 by U. S. Attorneys). 
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From an industry perspective, one major disadvantage of settlements (as opposed to 
judgments) is that the precedential and informational function that case law serves in a 
common law system is largely absent. Because the courts often are involved minimally in 
settlement agreements in the healthcare arena, or involved only in long-running discovery 
disputes, each new investigation presents legal uncertainty for the company subject to 
inquiry because the bounds of the law remain unknown. In a system that relies on the 
common law for cues regarding acceptable behavior, the lack of traditional precedent 
(leading to reliance on authoritative but nonbinding information) is unsettling and 
potentially inefficient.16 
 
Though CIAs (discussed further below) slightly alleviate this void of case law by 
providing insight into evolving enforcement expectations, they are binding only on the 
entity settling with the DOJ and the OIG.17 Investigators have wide discretion in 
determining the consequences of an investigation. And, at the time these high profile 
settlements were in their investigatory stages (e.g., the TAP investigation began with a 
whistleblower complaint in 1996),18 the pharmaceutical industry had not been issued 
compliance program guidance by the OIG. However, it is important to acknowledge the 
development of the Compliance Program Guidance (CPG) for the pharmaceutical 
industry19 and the comparable private guidances that seek to provide additional 
compliance benchmarks. 
 
II. Compliance Guidance for Pharmaceutical Manufacturers 
 
In May 2003, the OIG issued the long-awaited CPG for Pharmaceutical Manufacturers.20 
Before the CPG was issued for the pharmaceutical industry, the OIG already had released 
                                                 
16 See Krause, supra note 14, at 263 – 65 (noting that enforcement as a substitute for regulation results in 
fraud allegations settling without the benefit of judicial scrutiny or formal rulemaking). 
17 Cf. OIG, DHHS, Corporate Integrity Agreements—General Information [herein-after OIG, Corporate 
Integrity Agreements], available at oig.hhs.gov/fraud/cias.html (last visited May 24, 2007). 
18 Press Release, TAP, supra note 12. 
19 OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. 23,731 (May 5, 
2003) (notice), available at oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf. 
20 Id. By publishing CPGs, the OIG intends to provide clear direction on methods for avoiding healthcare 
fraud to the various sectors of the healthcare industry. All of the CPGs are modeled largely on the Federal 
Sentencing Guidelines, specifically Chapter 8 and the considerations for sentencing of organizations; the 
seven core elements of compliance programs that are emphasized in the CPGs, including the CPG for 
Pharmaceutical Manufacturers, are drawn from this document. Compare id. (detailing the seven core 
elements of an effective compliance and ethics program, which are (1) implementing written policies and 
procedures; (2) designating a compliance officer and compliance commit-tee; (3) conducting effective 
training and education; (4) developing effective lines of communication; (5) conducting internal monitoring 
and auditing; (6)  enforcing standards through well-publicized disciplinary guidelines; and (7) responding 
promptly to detected problems and undertaking corrective action), with U.S. SENTENCING 
GUIDELINES MANUAL § 8B2.1 (2004), available at www.ussc.gov/2004guid/CHAP8.pdf  (listing the 
same factors). Earlier versions of the Sentencing Guidelines list the same factors. E.g. U.S. SENTENCING 
GUIDELINES MANUAL § 8B2.1 (2003), available at www.ussc.gov/2003guid/8a1_2.htm. Despite the 
Supreme Court’s ruling that the Sentencing Guidelines were unconstitutional as a binding document on 
judges, they still serve as a source of direction for the OIG. Cf. United States v. Booker, 543 U.S. 220, 259 
(2005). 
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CPGs for many others in the healthcare industry, including clinical laboratories; 
hospitals; home health agencies; third-party medical billing companies; durable medical 
equipment, prosthetics, orthotics, and supply companies; hospices; Medicare + Choice 
organizations; nursing facilities; ambulance suppliers; and individual and small group 
physician practices.21 Though the practices of pharmaceutical sales representatives 
arguably had been violating the federal Anti-Kickback Statute for years,22 guidance for 
the pharmaceutical industry was slow in its arrival, seemingly leading pharmaceutical 
manufacturers to believe that aggressive sales practices were somehow exempt from 
federal fraud and abuse laws.23 
 
The CPG for Pharmaceutical Manufacturers cataloged a variety of important risk areas to 
consider as targets for compliance crackdown.24 The now-familiar areas of “significant 
concern” included: “(1) Integrity of data used by state and federal governments to 
establish payment amounts; (2) kickbacks and other illegal remuneration; and (3) 
compliance with laws regulating drug samples.”25 Although this list seems short, it 
encompasses all aspects of sales and marketing by pharmaceutical representatives that 
had been utilized until the date of the CPG. For instance, doctors had come to anticipate 
perks from their drug representatives, ranging from weekly pizza lunches for office staff 
to free tickets to Broadway performances to all expense-paid educational conferences in 
exotic locales.26 The OIG made it clear that such extras would be interpreted as improper 
                                                 
21 See OIG, DHHS, Fraud Prevention and Detection, Compliance Guidance, at 
oig.hhs.gov/fraud/complianceguidance.html (last visited May 24, 2007). 
22 See 42 U.S.C. § 1320a-7b(b) (2006); Jonathan K. Henderson & Quintin Cassady, Drug Deals in 2006: 
Cutting Edge Legal and Regulatory Issues in the Pharmaceutical Industry, 15 ANNALS HEALTH L. 107, 
128 – 30 (2006) (describing the Anti-Kickback Statute violations that have been on the OIG’s radar since 
the early 1990s). 
23 Nevertheless, the guidance has been relatively swift in its impact. See Marc J. Scheineson & Shannon 
Thyme Klinger, Lessons from Expanded Government En-forcement Efforts Against Drug Companies, 60 
FOOD & DRUG L.J. 1, 12 – 13 (2005) (asserting the importance of effective compliance and ethics 
programs in pharmaceutical companies given the focus on the industry); Harvey Yampolsky, 10 Years 
Later, A Healthy Dose of Fraud Enforcement for Pharmaceutical Companies, BUS. CRIMES BULL., Nov. 
2002, at 3 (noting the shift in prosecutorial focus to the pharmaceutical industry). 
24 OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. at 23,734 – 39. 
25 Id. at 23, 733. 
26 Concerned about physicians’ expectation that drug representatives would provide them with such “bread 
and butter” perks, the American Medical Association added a section to its Code of Medical Ethics entitled 
“Gifts to Physicians from Industry” that predated the OIG’s guidance by several years. See CODE OF 
MEDICAL ETHICS § E-8.061 (Council on Ethical & Judicial Affairs, Am. Med. Ass’n 2004) [hereinafter 
CODE OF MEDICAL ETHICS], available at tinyurl.com/27spdn (last visited May 24, 2007). This section 
can be striking in the direct reaction to the relationship between physicians and the pharmaceutical 
industry, noting both the pros and the cons; for instance: 
 
Many gifts given to physicians by companies in the pharmaceutical, device, and medical 
equipment industries serve an important and socially beneficial function. For example . . . funds 
for educational seminars and conferences. However, there has been growing concern about certain 
gifts from industry to physicians. Some gifts that reflect customary practices of industry may not 
be consistent with the Principles of Medical Ethics. To avoid the acceptance of inappropriate gifts, 
physicians should observe the following guidelines: (1) Any gifts accepted by physicians 
individually should primarily entail a benefit to patients. . . .  (2) Individual gifts of minimal value 
are permissible as long as the gifts are related to the physician’s work (eg, pens and notepads). . . . 
(5) Subsidies from industry should not be accepted directly or indirectly to pay for the costs of 
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remuneration that is paid to physicians to influence their prescribing practices, the very 
essence of improper remuneration under the Anti-Kickback Statute.27 
 
While no healthcare provider is required legally to follow a CPG, failure to do so could 
be a failure of best practices in the healthcare and the corporate context (discussed further 
below). Additionally, as a practical matter, failure to comply with a CPG is likely to 
result in whistleblower activity, which may subject the provider to the large settlements 
and CIAs mentioned above. Settlements with the DOJ are undesirable not only because 
of their unpredictability, publicity, and expense, but also because they result in CIAs.28 
CIAs are akin to the most exacting compliance program, with the added pressure of the 
program being subject to the vigilant supervision of the OIG (which now includes 
unannounced site visits).29 
 
Echoing the risk factors described in the CPG, a group of influential physicians published 
a policy proposal in the Journal of the American Medical Association (the Policy 
Proposal) asserting that all gifts to physicians, no matter how small, are improper and 
should cease because they create a conflict of interest between financial gain and patient 
                                                                                                                                                 
travel, lodging, or other personal expenses of physicians attending conferences or meetings, nor 
should subsidies be accepted to compensate for the physicians’ time. Subsidies for hospitality 
should not be accepted outside of modest meals or social events held as a part of a conference or 
meeting. . . . (7) No gifts should be accepted if there are strings attached. For example, physicians 
should not accept gifts if they are given in relation to the physician’s prescribing practices. 
 
Id. (emphasis added). The Code of Medical Ethics is nonbinding because it is not a source of legal 
authority. Nevertheless, physicians who take compliance seriously tend to follow this guidance to the 
extent possible. This, in turn, can affect physicians’ relationships with the sales force. See Troyen A. 
Brennan et al., Health Industry Practices that Create Conflicts of Interest: A Policy Proposal for Academic 
Medical Centers, 295 JAMA 429, 430–31 (2006), available at jama.ama-assn.org/cgi/reprint/295/4/429 
(last visited May 24, 2007) (advocating that pharmaceutical companies cease all gifts to physicians because 
they create a conflict of interest that is unavoidable even if the gift is de minimus). 
27 See OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. at 23,737; 42 
U.S.C. § 1320a-7b(b). 
28 See OIG, Corporate Integrity Agreements, supra note 17. Regarding the joint nature of the CIA, the OIG 
stated, “The [OIG] often negotiates compliance obligations with health care providers and other entities as 
part of the settlement of Federal health care program investigations arising under a variety of civil false 
claims statutes.” Id. 
29 See id. The OIG described corporate integrity agreements thus: 
 
A provider or entity consents to [CIAs] as part of the civil settlement and in exchange for 
the OIG’s agreement not to seek an exclusion of that health care provider or entity from 
participation in Medicare, Medicaid and other Federal health care programs. . . . 
Providers who settle these cases often deny that they were liable or that they committed 
the alleged conduct. 
 
Id. In the past, the OIG scheduled visits with healthcare providers who were subject to CIAs. Recently, 
however, the OIG announced that it will also conduct unannounced site visits to ensure compliance with 
CIAs is occurring on a day-to-day basis.  See OIG Shifting to Unannounced Site Visits to Assess CIA 
Compliance, Adherence, 12 HEALTH CARE DAILY (BNA) (April 26, 2007) (announced by an OIG 
official at a conference of the Health Care Compliance Association on April 23, 2007). 
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care.30 The authors noted that pharmaceutical companies have begun to self-regulate, 
calling the effort “commendable” yet failing to “resolve the crisis.”31 The Policy Proposal 
focused on marketing by pharmaceutical and medical device manufacturers aimed at 
medical school residents out of a concern that such marketing in academic medical 
centers may lead to career-long “bad habits” for physicians and, potentially, to ongoing 
conflicts of interest in the physician/patient relation-ship.32 Academic medical centers 
were also a focal point because they can act quickly and because immediate positive 
impact can be felt in such settings.33 The Policy Proposal attacked the “myth” of the de 
minimus gift and specifically called for stricter regulation by the federal government and 
the professional associations that issue ethical guidance to physicians and to the 
pharmaceutical industry.34 The authors argued that the current OIG guidance is too 
forgiving and fails to protect patients, and thus they suggested that academic medical 
centers should implement policies that go far beyond the bounds of the CPG.35 The 
Policy Proposal strongly suggested that pharmaceutical manufacturers and medical 
device companies that do not respond with more stringent compliance programs may 
expect much more stringent ethical codes (if not formal federal regulations) in the near 
future, given that dissatisfaction and caution now radiate from the relationship that had 
provided the industry with so much consideration historically.36 
 
Strangely, the Policy Proposal did not directly mention the Pharmaceutical Research and 
Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals 
(the PhRMA Code), which was disseminated before the CPG for Pharmaceutical 
Manufacturers was published.37 The PhRMA Code may not have been mentioned by the 
Policy Paper because it has many elements that overlap with and are consistent with the 
CPG for Pharmaceutical Manufacturers, though a few aspects of the PhRMA Code are 
even stricter than the OIG recommends and might have enhanced the analysis in the 
Policy Proposal.38 For instance, the PhRMA Code specifically delineates appropriate 
                                                 
30 Brennan et al., supra note 26, at 430–31 (arguing that public and private authorities are wrong to assume 
that small gifts are not harmful to the physician’s neutral decision-making ability). 
31 Id. at 429 – 30. 
32 See id. at 430. 
33 Id. 
34 Id. at 430 – 31. 
35 Brennan et al, supra note 26, at 430 – 32. 
36 Similarly, Senator Grassley has added to the intense scrutiny by making comments on the “cozy” 
relationship between FDA leadership and the pharmaceutical industry and the conflicts of interest that may 
exist. Press Release, U.S. Senator Chuck Grassley, Grassley Comment on the Opportunity for New FDA 
Leadership (Sept. 23, 2005), available at tinyurl.com/yw2qqb (last visited May 24, 2007). 
37 See Brennan et al., supra note 26, at 430; see generally PHARM. RESEARCH & MFRS. OF AM. 
(PHRMA), CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS (2004) [hereinafter 
PhRMA CODE], available at www.phrma.org/fi les/PhRMA%20Code.pdf (last visited May 24, 2007). 
38 Senator Grassley has commented on the insufficiency of the PhRMA Code, calling for FDA regulation to 
supplant its direct-to-consumer advertising suggestions. See, e.g., Memorandum from Jill Kozeny for U.S. 
Senator Chuck Grassley, United States Commission on Finance 1 (Aug. 2, 2005), available at 
www.senate.gov/~finance/press/Gpress/2005/prg080205a.pdf (last visited May 24, 2006). Senator Grassley 
commented that the PhRMA guidelines on direct-to-consumer (DTC) advertising were inadequate and 
promoting proposed legislation that would require the FDA to require review of all DTC prior to 
placement. 
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affiliation with and payment for educational conferences, but the OIG simply states that 
continuing medical education and other conferences should not be used to influence 
physicians’ decision-making.39 (On the other hand, the OIG addresses drug samples and 
their distribution to physicians at length, and the PhRMA Code does not discuss them.)40 
Other codes of conduct also went unmentioned in the Policy Proposal, such as the AMA 
Code of Medical Ethics section regarding “Gifts to Physicians from Industry”; the 
AdvaMed Code of Ethics for Device Manufacturers; and the Health Industry Group 
Purchasing Association Code on Interactions with Healthcare Professionals. These codes 
of conduct add to the potentially conflicting advice regarding effective compliance 
programs, and the Policy Proposal might have been stronger if it attempted to reconcile 
its suggestions with existing public and private guidances.41 
 
Emerging developments indicate that a compliance program that comports with extant 
OIG authority may not suffice. The sheer number of ethical codes signifies the 
tremendous amount of attention that the pharmaceutical industry has received in the past 
few years. Nonetheless, it can be difficult to grasp exactly what is expected of the 
industry. The authors of the Policy Proposal did recognize that most pharmaceutical 
companies appear to have active compliance programs in place.42 But, to have an active 
compliance program may not be adequate. Given the enhanced reimbursement 
relationship that the pharmaceutical industry will have with the government by virtue of 
Medicare Part D, the industry may need to be more adaptable and aggressive in 
compliance than previously contemplated. 
 
III. The Medicare Modernization Act and Medicare Part D 
 
                                                 
39 Compare PhRMA CODE, supra note 37, at 9, with OIG Compliance Program Guidance for 
Pharmaceutical Manufacturers, 68 Fed. Reg. 23,731, 23,738 (May 5, 2003) (notice), available at 
oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf (last visited May 24, 2007). 
40 See OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. at 23,731. 
41 See generally ADVANCED MED. TECH. ASS’N, CODE OF ETHICS ON INTERACTIONS WITH 
HEALTH CARE PROFESSIONALS (2003), available at www.advamed.org/publicdocs/coe_with_faqs_4-
15-05.pdf (last visited May 24, 2007); CODE OF MEDICAL ETHICS, supra note 26; HEALTH INDUS. 
GROUP PURCHASING ASS’N, CODE OF CONDUCT PRINCIPLES (2002), available at 
www.higpa.org/pressroom/2002/7-29HIGPACode.pdf (last visited May 24, 2007). An excellent 
comparison chart of the various codes has been created and updated by Kathleen McDermott and can be 
found on the American Health Lawyers Association website for members at 
www.healthlawyers.org/Template.cfm?section=Practice_Corner&template=/MembersOnly.cfm&ContentI
D=4548. 
42 See Brennan et al., supra note 26, at 429 (noting that pharmaceutical manufacturers have been regulating 
themselves more stringently). 
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The strong likelihood of increasing scrutiny is enhanced exponentially by the MMA.43 
The import of this law for the pharmaceutical industry cannot be understated. After 
decades of Medicare paying primarily for services and durable goods through Medicare 
Parts A and B, Congress decided that outpatient drugs would be reimbursed through a 
new benefit, Medicare Part D.44 Though Medicaid has long included pharmaceuticals in 
its list of reimbursable program elements, the creation of a new “part” of Medicare is a 
milestone.45 
 
To give a brief overview of the changes in reimbursement resulting from the MMA: the 
few drugs that had been covered by Medicare Part A and Part B will continue to be 
covered by those parts and will not be included in the Part D program.46 The method of 
calculating reimbursement for many Part B drugs will be changed from 95% of the 
average wholesale price (AWP) to a system that has its foundation in CIAs with 
pharmaceutical manufacturers, called the Average Sales Price (ASP).47 Reimbursement 
will be 106% of either the ASP or the Wholesale Acquisition Cost (WAC), depending on 
the role the drug company plays.48 To ensure that reported prices reflect actual costs, the 
OIG will compare the ASP or WAC to the “widely available market price” (WAMP) and 
to the Medicaid Average Manufacturer Price (AMP).49 This system allows physicians 
                                                 
43 See Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 
117 Stat. 2066 (codified as amended in scattered sections of 21, 26, and 42 U.S.C.). The MMA included 
many other changes to the health-care system that are only tangentially related to Medicare, such as 
facilitating the expansion of health savings accounts in such a way that they more closely resemble 
individual retirement accounts. See, e.g. id. § 233, 117 Stat. at 2209; see also John V. Jacobi, Consumer-
Directed Health Care and the Chronically Ill, 38 U. MICH. J.L. REFORM 531, 550 (2005) (describing 
health savings accounts as a microcosm of the push for consumer-directed health plans and the codification 
of HSAs in the MMA as an example of their continued popularity). 
44 Medicare Part A, the hospital insurance program, pays hospitals and other institutional “providers” for 
their services to Americans over the age of sixty-five who have paid into the Social Security system. See 42 
U.S.C. § 1395c (2005). Drugs used as part of a covered inpatient hospital and/or nursing home stay have 
been covered by Medicare Part A. See id. §§ 1395c, 1395(a)(1)(S). Medicare Part B, called Supplementary 
Medical Insurance, is a voluntary benefit in which seniors who receive Part A may pay to participate for a 
premium that increases yearly (at least now, although for a long time it remained fl at). See id. §§ 1395j, 
1395r(a)(1). Medicare Part B has paid for drugs that cannot be self-administered; a typical example is drugs 
used in chemotherapy to kill cancerous cells (oncolitics). See id. § 1395u(o). 
45 Medicare Part C is not really a “part” of Medicare, meaning it is not a separate benefit in the way that 
Parts A, B, and D are “parts.” Instead, Part C simply creates a way for managed care companies to service 
Medicare beneficiaries by combining the other parts of Medicare; it does not add a new type of coverage 
per se. See 42 U.S.C. §§ 1395w-21 to w-29 (2003 & Supp. 2005). 
46 CTRS. FOR MEDICARE & MEDICAID SERVS. (CMS), DHHS, MEDICARE PART B VERSUS 
PART D COVERAGE ISSUES 1 (Draft July 27, 2005), available at 
www.cms.hhs.gov/PrescriptionDrugCovGenIn/Downloads/PartBandPartDdoc_07.27.05.pdf (last visited 
May 24, 2007) (providing a forty-page chart describing whether Medicare Part B or Part D should be billed 
for certain drugs). 
47 See Alex Sugerman-Brozan & James Woolman, Drug Spending and the Average Wholesale Price: 
Removing the AWP Albatross from Medicaid’s Neck, 13 HEALTH CARE POL’Y REP. (BNA) (2006), 
available at healthcenter.bna.com/pic2/hc.nsf/id/BNAP-6G8NPZ?OpenDocument (last visited May 24, 
2007). 
48 See MMA § 303(c). 
49 See id. 
Journal of Health Law Vol. 40 No. 2 
either to use a competitive bidding process for the drugs supplied in-office or to rely on 
the ASP calculation.50 
 
While some cost-reporting methodologies are changing, the old pitfalls for drug 
reimbursement appear to remain under the MMA in the sense that pharmaceutical 
manufacturers are given somewhat vague standards for describing and proving the actual 
cost of drugs for Medicare. This is not far different from the problems that have existed 
historically under the AWP system. The intricacy of the calculations to determine prices 
for Part B drugs alone reveals the potential number of compliance pitfalls that await 
pharmaceutical manufacturers. Although the calculus for reporting prices is elaborate, it 
seems to be relatively open-ended (in comparison to the systems for reimbursement of 
other healthcare items and services) and thus increases the potential for eventual charges 
of wrongdoing. 
 
Medicare has never had such a vested interest in the workings of the pharmaceutical 
industry.51 The scope of the MMA signals the magnitude of the changes to Medicare in 
creating this benefit, which in turn indicates the scale of the impact on the pharmaceutical 
industry both in quotidian operations and in the long-term compliance realm. Although 
Medicaid programs have covered outpatient drugs for many years, many Medicaid Fraud 
Control Units have not had the mandate or resources to decipher the complex rules 
surrounding the AMP, rebates, and other methods of calculating the amount that 
Medicaid reimburses for drugs.52 Some observers perceive that the pharmaceutical 
industry had “beaten” the Medicaid reimbursement system for years, noting that the 
repercussions had been relatively minor until recently.53 The perceived lack of 
prosecutorial resources at the state and federal level is bound to change now that more 
federal money for enforcement is expected to flow to this sector of the healthcare 
industry. 
 
Direct reimbursement by Medicare also means that the DOJ will have many more 
opportunities to regulate the industry through enforcement of the federal False Claims 
Act.54 In the past, whistleblowers developed novel legal theories to bring actions under 
the False Claims Act, attempting to prove the chain of causation to reach the deep 
pockets of the pharmaceutical manufacturers.55 Now such proof will be more 
                                                 
50 See id. § 303(d). 
51 See ALICE G. GOSFIELD, MEDICARE AND MEDICAID FRAUD AND ABUSE § 1.31 (2005) 
(asserting that the enactment of the MMA will subject the pharmaceutical industry to the focus of fraud and 
abuse law because of the new regulatory scheme that applies directly to the industry); Henderson & 
Cassady, supra note 22, at 108–09 (describing some of the reasons for the increased prosecutorial interest 
in the pharmaceutical industry).  Also, with the new Democratic majority in Congress, the push for 
Medicare negotiation of drug prices may serve to further in crease this intensified focus, as even less room 
will exist for drug pricing to be peripatetic. 
52 Cf. 42 U.S.C. § 256b (2005). 
53 See Krause, supra note 14, at 266 – 72 (using the trends of fraud and abuse prosecutions in the 
pharmaceutical industry as an example of how such prosecutions can change the law when Congress and/or 
agencies fail to act against a particular sector of the healthcare industry). 
54 See generally 31 U.S.C. §§ 3729 – 3733 (2005). 
55 See, e.g., United States ex rel. Franklin v. Parke-Davis, No. Civ.A. 96-11651PBS, 2003 WL 22048255, at 
*4 – 5 (D. Mass. Aug. 22, 2003); United States ex rel. Franklin v. Parke-Davis, 147 F. Supp. 2d 39, 50–53 
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straightforward. Instead of relying on an attenuated line of information, influence, and 
purchase, prosecutors will be able to simply show the direct link between the 
pharmaceutical manufacturer and the Medicare reimbursement. Already a favorite tool of 
federal prosecutors for prosecuting healthcare fraud, the False Claims Act has the 
potential to become even more popular for regulating the pharmaceutical industry. The 
pharmaceutical industry will not be under the microscope alone; Part D contractors and 
Medicare Advantage Plans already face challenges regarding their receipt of federal 
monies as well.56 Medicare Part D, however, will add to the federal examination of the 
industry immensely; CMS has stated that it will enforce the rights of Medicare 
beneficiaries stringently in the context of Medicare Part D and will carefully examine the 
sales practices of the entities offering the drug plan.57 
 
Further, in the Special Advisory Bulletin on Patient Assistance Programs for Medicare 
Part D Enrollees, the OIG warned that patient assistance programs raise anti-kickback 
concerns be-cause pharmaceutical manufacturers’ subsidies for Part D drugs may be 
perceived as a payment to influence the purchase of an item directly reimbursed by 
Medicare—the very definition of a kickback.58 As the OIG described, such practices raise 
the “usual risks of fraud and abuse associated with kickbacks, including steering 
beneficiaries to particular drugs; increasing costs to Medicare; providing a financial 
advantage over competing drugs; and reducing beneficiaries[’] incentives to locate and 
use less expensive, equally effective drugs.”59 Beneficiary protection is just one aspect of 
the predicted increase in federal scrutiny of pharmaceutical manufacturers. 
 
The price for the privilege of Medicare reimbursement has always been subjection of 
providers to the corpus of fraud and abuse laws. With the pre-MMA success of the DOJ 
and OIG in negotiating large settlements with pharmaceutical manufacturers for alleged 
Medicaid fraud and/or abuse, and given that significantly more federal money will be 
                                                                                                                                                 
(D. Mass. 2001) (in which a relator almost successfully enforced FDA regulations through a civil False 
Claims Act theory of liability; Pfizer ultimately settled the case and agreed to enter a CIA). 
56 See Robert Pear, Methods Used by Insurers Are Questioned, N.Y. TIMES, May 7, 2007 (describing 
investigations into improper enrollment methods used by Medicare Advantage companies); see also Part D 
Drug Benefit, Part D Fraud Opportunities Abound; PDPs Will Be Key to Detection, 16 MEDICARE REP. 
(BNA) 1151 (Sept. 30, 2005) (reporting on Assistant U.S. Attorney Jim Sheehan and private attorney 
Elizabeth Carder-Thompson’s predictions on the fraud and abuse possibilities that await pharmacies and 
Part D plans). 
57 See Press Release, CMS, DHHS, Medicare Expands Efforts to Fight Fraud (Oct. 7, 2005), available at 
www.cms.hhs.gov/apps/media/press/release.asp?Counter=1690 (last visited May 24, 2006). Additionally, 
the reimportation of drugs from other countries has been folded into the Medicare drug benefit 
conversation, which adds to industry pressure. See Kelly McCormack & Bob Cusack, AARP Edges Away 
from Drug Imports, THE HILL, Jan. 4, 2006, at 1, copy available at tinyurl.com/2snyok (last visited May 
24, 2007); Henry J. Kaiser Family Foundation, Prescription Drugs: AARP Analysis Finds Medicare Drug 
Benefi t Will Save Seniors More Money than Prescription Drug Reimportation, DAILY REPORTS, Jan. 4, 
2006, available at www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=34589 (last visited May 
24, 2007). 
58 See Publication of OIG Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D 
Enrollees, 70 Fed. Reg. 70,623, 70,625 (Nov. 22, 2005) (notice). 
59 Id. at 70,625. The OIG goes on to suggest that independent charities created by pharmaceutical 
manufacturers might be able to properly assist beneficiaries who struggle with drug costs. See id. at 70,626 
– 27. 
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flowing directly to pharmaceutical manufacturers through the Part D benefit, it appears 
only a matter of time before investigations of pharmaceutical companies for Medicare 
fraud follow.60 Because the system of payment for drug costs has become more 
complicated under the MMA, pharmaceutical manufacturers will not only be subject to 
increased scrutiny but may also be unable to defend their decisions by relying on 
arguably vague guidance. The Physicians At Teaching Hospitals (PATH) audits at 
academic medical centers serve as a reminder that it is difficult for a provider to 
successfully defend its actions when reimbursement guidance is unclear—or even 
nonexistent.61 To avoid such pitfalls, the pharmaceutical industry may need to reach 
beyond the OIG’s current vision of compliance to incorporate best practices so that board 
members understand that they too should be aware of, and may be held responsible for, 
challenges facing the industry. 
 
IV. The Sarbanes-Oxley Act and the Pressure of Best Practices 
 
The American Competitiveness and Corporate Accountability Act of 2002 (known as the 
Sarbanes-Oxley Act, in recognition of the bill’s main sponsors in the Senate) set forth 
procedures and systems for publicly traded corporations that contribute to the demand for 
high levels of proactive self-policing.62 The legislation has created an atmosphere of 
intense inquiry for publicly traded companies that has forced a wide variety of 
corporations to take a hard look at heretofore under-examined practices such as audits, 
internal board practices, methods of operation, and document destruction; and rules have 
been created for these and other issues.63 The Sarbanes-Oxley Act preceded the CPG for 
pharmaceutical manufacturers and was a first taste of active corporate policing. Some 
criticize the Sarbanes-Oxley Act for creating a “loud bark” with “no bite;”64 even so, it 
raised public visibility not only of the malfeasance of certain corporations, but also of the 
judicial concept of best practices.65 Many companies have attempted to implement best 
practices, even though such measures are not specifically codified in the Sarbanes-Oxley 
Act.66 
                                                 
60 The OIG Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees 
indicates that the investigation and enforcement arm of the Medicare program has already been looking for 
fraudulent schemes. See id. at 70, 628. 
61 See OIG, DHHS, SEMIANNUAL REP. at 5–6 (Oct. – Mar. 1998) (describing the PATH audit initiative). 
62 Sarbanes-Oxley Act, Pub. L. No. 107-204, 116 Stat. 745 (codified in scattered sections of 11, 15, 18, 28, 
and 29 U.S.C). 
63 See BOARDSOURCE & INDEPENDENT SECTOR, THE SARBANES-OXLEY ACT AND 
IMPLICATIONS FOR NONPROFIT ORGANIZATIONS 2 (2003) [hereinafter BOARDSOURCE & 
INDEPENDENT SECTOR], available at www.independentsector.org/PDFs/sarbanesoxley.pdf (last visited 
May 24, 2007). This guidance document for nonprofits notes that the whistleblower protections and new 
document destruction rules apply to all corporate entities, whether for-profit or nonprofit, which is 
important for the healthcare industry as a whole. See id. at 9 – 10; see also William S. Duffey, Jr., 
Corporate Fraud and Accountability: A Primer on Sarbanes-Oxley Act of 2002, 54 S.C. L. REV. 405 
(2002) (discussing the highlights of Sarbanes-Oxley). 
64 See J. Robert Brown, Jr., The Irrelevance of State Corporate Law in the Governance of Public 
Companies, 38 U. RICH. L. REV. 317, 320–21 (2004) (arguing that the Sarbanes-Oxley Act allows the 
same types of scandals to occur to which it was drafted in reaction). 
65 See BOARDSOURCE & INDEPENDENT SECTOR, supra note 63, at 2. 
66 See id. 
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Examples of best practices evolving to become part of a corporation’s requirements have 
been displayed in the Disney cases that pervaded Delaware courts for a time.67 The court 
in Brehm v. Eisner noted that “[a]spirational ideals of good corporate governance 
practices for boards of directors that go beyond the minimal legal requirements of the 
corporation law are highly desirable. . . . But they are not required by the corporation law 
and do not define standards of liability.”68 In the same vein, the court in In re Walt 
Disney Company stated that “best practices of corporate governance include compliance 
with fiduciary duties. Compliance with fiduciary duties, however, is not al-ways enough 
to meet or to satisfy what is expected by the best practices of corporate governance.”69 
Despite reinforcement of the best practices ideal in these high-profile cases, no case 
specifically delineates the governing principles that constitute best practices. 
 
Recognizing the gap between ideal and doctrinal reality, former Delaware Supreme Court 
Chief Justice Veasey set forth a number of principles in 2005 intended to guide directors 
in understanding the concept of best practices and to mitigate the outcome if a 
corporation is reviewed by a court or administrative agency.70 Justice Veasey’s 
suggestions range from ideals, such as embracing best practices, to practical benchmarks, 
such as commanding directors to understand their corporation’s business, market, 
competition, financial controls, and financial disclosures.71 
                                                 
67 See, e.g., Brehm v. Eisner, 746 A.2d 244, 256 (Del. 2000); In re Walt Disney Co. Derivative Litig., No. 
15452, 2005 Del. Ch. LEXIS 113, *1 (Del. Ch. Aug. 9, 2005). 
68 Brehm, 746 A.2d at 256. 
69 In re Walt Disney Company Derivative Litig. at *147. 
70 See E. Norman Veasey, What Happened in Delaware Corporate Law and Governance from 1992-2004? 
A Retrospective on Some Key Developments, 153 U. PA. L. REV. 1399, 1506 – 08 (2005). 
71 See id. Justice Veasey took care to set forth a full list of guidelines, which are as follows:  
• Be careful and thoroughly investigate the integrity and financial position of a company before 
agreeing to serve as a director. 
• Embrace best practices in governance processes. 
• Appoint a strong independent board leader, whether a nonexecutive chair or a lead director. 
• Be certain that all directors are financially literate. 
• Be certain that the board has regular executive sessions. 
• Pay special attention to the board agenda—is the board focused on the right issues and is the board 
involved in making that determination? 
• Make sure you have a reasonably complete understanding of the company’s business, competitive 
environment, financial controls, and financial disclosures. The same is true of the need to have a 
thorough understanding of a particular transaction being considered for board action. 
• Pay special attention to the board’s information needs—does the board have access to the 
information it needs, and is the board in control of determining what information it needs? 
• Actively engage in board discussions and deliberations with healthy skepticism always and 
constructive criticism when called for. There is no such thing as a “stupid” question. 
• Review board and committee minutes—and ask that they be circulated to all directors within a 
week for comments (not approval; that can wait)—to ensure they accurately reflect the matters 
considered, and capture the general extent and nature of the board’s discussions, deliberations, 
considerations, decisions, and directions (not a transcript of who said what). 
• Insist that management keep track of and report progress on items that came before the board and 
resulted in board decisions or directions. 
• Take special care in reviewing registration statements. 
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The last element reflects the principles found in the landmark case In re Caremark.72 The 
Caremark court described healthcare directors’ fiduciary duties to include a “duty to 
monitor,” meaning that directors must understand how their company implements its 
compliance program and ensure that an “information and reporting system” exists, almost 
rendering the board a super-compliance committee.73 
 
The command to understand the market, its controls, and a company’s internal response 
to compliance constraints is particularly important for pharmaceutical companies 
instituting best practices because they are part of a highly complex and highly regulated 
market. Many companies now are subject to the rules of the FDA, CMS, and the SEC 
(though, unlike other healthcare providers, they are not also subject to state licensure 
laws). This means that pharmaceutical companies and their boards of directors are under 
pressure to act not only within the confines of the Sarbanes-Oxley Act, but also within 
the OIG’s compliance guidance, the private ethical codes, FDA rules, and Medicare 
rules.74 The close inspection that is encouraged by the Sarbanes-Oxley Act and best 
practice ideals compounds the impact of these other legal developments. Directors must 
adhere to the usual fiduciary duties and ensure that, in the spirit of best practices, their 
companies are compliant with the many authorities that attempt to guide them. 
 
V. HIPAA Privacy Regulations 
 
An additional source of potential scrutiny, liability, and con-fusion is the far-reaching net 
of HIPAA and its privacy regulations, especially with recent indications that the Office 
for Civil Rights intends to crack down on violations of the privacy rules. Congress 
enacted HIPAA to ensure portability of health insurance from one employer to another. 
Whatever its original intent, however, the impact of HIPAA privacy regulations has been 
to affect the privacy of medical records in such a way that the marketing practices of the 
pharmaceutical industry may be permanently altered.75 
 
                                                                                                                                                 
• Make sure disclosures are clear and that you understand them; ask management for assurances and 
representations. 
• Ask independent auditors for assurances of the integrity of the reporting and their due diligence. 
• Understand what you sign. 
• Beware of a CEO who manages to the market, or who tries unduly to manage the board. 
• Resist a culture of complacency when things look to be running well. 
• Rely in good faith on well-chosen experts. 
 
Best practices must be realistic. Do not undertake to jump over an impossibly high bar of best practices. 
Failure to follow your own guidelines is not a good optic in court. 
 
Id. 
72 See In re Caremark Int’l, Inc. Deriv. Litig., 698 A.2d 959, 968–70 (Del. Ch. 1996) (discussing the 
board’s duty to monitor corporate activities). 
73 Id. at 970–71. 
74 See Scheineson & Klinger, supra note 23, at 1 – 2. 
75 See Health Insurance Portability and Accountability Act, Pub. L. No. 104-191, 110 Stat. 1936 (1996). 
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The HIPAA privacy regulations apply to “Covered Entities,” a term that is defined to 
include healthcare providers that engage in certain electronic healthcare transactions, 
health information clearinghouses, and health plans.76 Pharmaceutical companies 
generally are considered to be none of these;77 however, because clinical trials often 
involve human subjects, Covered Entity status may be imposed on pharmaceutical 
manufacturers in some circumstances.78 The privacy regulations also apply to “Business 
Associates” of Covered Entities, and Business Associates must adhere by contract to the 
privacy regulations (rather than by direct application); notably, the regulation-defined 
status of being a Business Associate depends on what the associate does, not what it is.79 
Although many hospitals and other healthcare providers have attempted to enter Business 
Associate Agreements with pharmaceutical manufacturers to bind them to the HIPAA 
regulations, the industry generally does not perform services that bring it within the 
definition of a Business Associate and such agreements were avoided in many cases.80 
 
Nonetheless, certain practices of sales representatives raise concerns under the privacy 
regulations. For example, “shadowing” a physician while observing patients and/or 
participating in the physician’s interaction with patients raise HIPAA privacy concerns if 
the patient does not have an opportunity to consent or to refuse the drug representative’s 
presence in the examining room.81 This may pose even more difficulties for the medical 
device industry, which traditionally employs medically trained sales representatives who 
train physicians in the operating room. Other common practices of sales representatives 
                                                 
76 See 45 C.F.R. pts. 160, 164 (2005). 
77 The industry may be subject, however, to state privacy laws that are considered more “strict” than 
HIPAA or that have a different basis on which to protect the privacy of patient records, especially if they 
pay pharmacies for patient information or to solicit patients on their behalf. For example, the drugstore 
chain Eckerd was investigated by the attorney general of Florida for failure to seek unambiguous 
authorization from customers to be solicited by Eckerd on behalf of drug companies. See Press Release, 
Fla. Attorney Gen., Eckerd Endows $1 Million Ethics Chair at FAMU, Revises Policies to Help Protect 
Patient Privacy (July 10, 2002), available at 
http://myfloridalegal.com/newsrel.nsf/newsreleases/28930326B8C35ADE85256BF200544B94 (last visited 
May 24, 2007). 
78 See Meredith Kapushion, Hungry, Hungry HIPAA: When Privacy Regulations Go Too Far, 31 
FORDHAM URB. L.J. 1483, 1499 (2004) (observing that HIPAA privacy regulations have made clinical 
research more difficult for all parties involved in clinical trials). 
79 See 45 C.F.R. § 160.103. 
80 As with all industries that are subject to frequent litigation, avoidance of un-necessary regulatory 
commitments was certainly a reason for reluctance to sign business associate agreements. 
81 Shadowing is clearly a method of marketing that requires the patient’s authorization. See OFF. FOR 
CIVIL RIGHTS, DHHS, FACT SHEET: PROTECTING THE PRIVACY OF PATIENTS’ HEALTH 
INFORMATION (Apr. 14, 2003), available at www.hhs.gov/news/facts/privacy.html (last visited May 24, 
2007). The Office for Civil Rights stated: 
 
The final privacy rule sets new restrictions and limits on the use of patient information 
for marketing purposes. Pharmacies, health plans and other covered entities must first 
obtain an individual’s specific authorization before disclosing their patient information 
for marketing. At the same time, the rule permits doctors and other covered entities to 
communicate freely with patients about treatment options and other health-related 
information, including disease-management programs. 
 
Id. 
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can be affected as well; for example, the unrestricted access to patient records that they 
once enjoyed in physician offices and hospitals cannot continue under HIPAA 
constraints.82 Patient information should be de-identified before being shared because it 
would no longer be considered protected health information. But, this would be an 
onerous process that places a significant administrative burden on the physician and 
renders information potentially less useful for the pharmaceutical company.83 Of course, 
these difficulties are solved if the provider can obtain unambiguous written patient 
authorization for the sales representative’s presence and for file-sharing, but not all 
patients will agree to execute such a consent. 
 
HIPAA compliance also provides another rationale for DHHS to monitor the activities of 
the pharmaceutical industry and its sales force. Many federal prosecutors have appeared 
interested to begin investigating sales and marketing efforts by the industry, and HIPAA 
may complement the False Claims Act efforts.84 The industry thus faces the task of 
finding ways to obtain authorizations whenever patient information is sought. In the years 
following the initial implementation of the privacy regulations, patient authorizations 
have become a regular part of the health-care system; as a result, and assuming that the 
authorizations include language that allows access by pharmaceutical partners, the need 
for authorizations may be less of a concern than the complicating effect that HIPAA may 
have on the industry overall. HIPAA adds to the many regulatory demands on the 
pharmaceutical industry and potentially to physicians’ conflicts of interest as described in 
the Policy Proposal. 
 
VI. Comparison to History of Reimbursement for the Hospital Industry 
 
The evolution in hospital reimbursement may serve as a cautionary example for the 
pharmaceutical industry regarding the effects of scrutiny by the federal government, 
private payors, and the media. Hospital payment systems were developed at a time when 
surgery became an everyday occurrence that required uniform and complex physical 
support structures as well as reliable support staff.85 Rather than continuing to depend on 
charity, hospitals sought payment from patients, who paid whatever amounts hospitals 
billed for providing a service (often to the detriment of physicians).86 Although 
physicians and hospitals alike loathed the idea of intermediaries between healthcare 
service and direct patient payment, health insurance (in the form of Blue Cross and Blue 
Shield) emerged in the early 1900s, modifying the hospital payment model slightly by 
                                                 
82 Because exceptions for sharing information exist for public health reasons, it is unlikely that FDA 
regulations requiring reporting of errors and defects will create HIPAA violations, especially because the 
exception for public health includes reporting to the FDA. See 45 C.F.R. § 164.512(b)(iii). 
83 See id. § 164.502 (excluding de-identified information from the definition of protected health 
information). 
84 See Bruce Japsen, Targets Change in Drug Probes; Manufacturers Under Scrutiny, CHI. TRIB., Dec. 
27, 2001, at N1. 
85 See PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE, 145–79 
(discussing the history of hospitals in the United States from almshouses to scientific centers of medical 
care and from charitable institutions to businesses). 
86 See id. at 161, 299. 
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adding a third party to the payment process.87 The Blue Cross/Blue Shield format became 
a standard model for American health insurance and helped shape the construction of 
Medicare in the 1960s.88 Effective lobbying ensured the place of Blue Cross/Blue Shield 
in the Medicare world in the form of fiscal intermediaries and carriers.89 Thus, for many 
years Medicare Part A payment mirrored the Blue Cross/Blue Shield system, meaning 
that hospitals were paid reasonable costs as set by the hospital.90 
 
Although this system was lucrative and fairly simple administratively for hospitals, it was 
expensive for the federal government and the taxpayer.91 After attempting a reasonable 
cost system in the 1970s,92 Medicare moved to a more controlling structure in the early 
1980s that is still used, known as the inpatient prospective payment system (IPPS).93 
Through the Tax Equity and Fiscal Responsibility Act of 1982,94 Congress instituted a 
system wherein hospitals are required to submit cost reports to account for their expenses, 
which were no longer determined by direct costs. Instead, an algorithm accounts for the 
patient’s diagnosis upon discharge and creates a national monetary value for the cost of 
treating that patient, which is then adjusted to account for geographic differences in 
costs.95 
 
                                                 
87 See id. at 295 – 98. 
88 See Clark C. Havighurst, Freedom of Contract: The Unexplored Path to Health Care Reform, in 
AMERICAN HEALTH CARE: GOVERNMENT, MARKET PROCESSES, AND THE PUBLIC 
INTEREST 145, 154 (Roger D. Feldman ed., Transaction Publishers 2000). A microcosmic example of this 
progression can be seen in New York’s insurance market. See Consumers Union of U.S., Inc. v. State of 
New York, 840 N.E.2d 68 (2005). The facts of this case trace the history of Associated Health Service, 
which became Empire Blue Cross/Blue Shield, a hospital service plan, then a Medicare fiscal intermediary, 
and later a commercial insurer with a variety of health insurance products. See id. at 68 – 78 
89 Under the MMA, carriers and intermediaries will be called simply “contractors.” See Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, § 911, 117 Stat. 
2066, 2378 (codified at 42 U.S.C. §§ 1395h, 1395kk-1, 1395u (2003)). 
90 See R. Brent Rawlings & Hugh E. Aaron, The Effect of Hospital Charges on Outlier Payments Under 
Medicare’s Inpatient Prospective Payment System: Prudent Financial Management or Illegal Conduct?, 
14 ANNALS HEALTH L. 267, 269–71 (2005) (describing the cost-based retrospective payment system 
under which hospitals received the reasonable cost of their services so long as the service was covered by 
Medicare). 
91 The General Accounting Office issued a report in 1986 that Blue Cross plans were not different from 
commercial insurers in any material respect, and that they did not warrant the designation of “social welfare 
organization” that had led to the federal tax-exempt status. See U.S. GEN. ACCOUNTING OFFICE, 
HEALTH INSURANCE: COMPARING BLUE CROSS AND BLUE SHIELD PLANS WITH 
COMMERCIAL INSURERS 21 (1986), available at archive.gao.gov/d4t4/130462.pdf; see also 
Consumers Union of U.S., Inc., 840 N.E.2d at s72 – 73. This financial blow to insurers also led to more 
meager funds for hospitals and contributed to scrutiny of hospital cost-reimbursement systems. 
92 Nina J. Crimm, Evolutionary Forces: Changes in For-Profit and Not-For-Profit Health Care Delivery 
Structures; A Regeneration of Tax Exemption Standards, 37 B.C. L. REV. 1, 18 – 19 (1995) (discussing the 
failure of the reasonable cost system in Medicare). 
93 Medicare now uses prospective payment systems for most healthcare providers. Id. at 19 – 20. The drug 
industry is an obvious exception. 
94 Tax Equity and Fiscal Responsibility Act of 1982, Pub. L. No. 109-80, 96 Stat. 324 (codified as amended 
in scattered sections of 26 U.S.C.). 
95 Social Security Amendments of 1938, Pub. L. No. 98-21, 97 Stat. 65, 152, 162, 163 (1983) (codified as 
amended at 42 U.S.C. §§ 1395f, 1395y, 1395ww (2005)). 
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This simplified description helps to illustrate that complex forms of cost containment 
have been created and imposed on Medicare participating providers and can be 
anticipated again.96 After hospitals had been encouraged for years to lower expenses, 
cost-restraint systems ultimately were created for them, not only through the Medicare 
IPPS system, but also through commercial insurers’ restriction of cost by movement to 
“lower of cost or charge” reimbursement, and ultimately through managed care and 
negotiated rates.97 In other words, hospitals were subject to restraints, arguably because 
they refused to control themselves.98 A historical examination of hospital reimbursement 
reminds the pharmaceutical industry (as the most recently added Medicare provider) that 
cost containment can, and likely will, be imposed on the services and products to be 
reimbursed under Part D.99 
 
The cost and sales price of drugs has been a hotly debated topic in the public and the 
media, and the calculus for drug reimbursement under Medicare Part D, although quite 
complex, currently contains no cost-control measures.100 For example, prescription drug 
plans (PDPs, the stand-alone drug benefit) and Medicare Advantage Plans (MA Plans, 
Medicare managed care, which com-bines Parts A, B, and D) set the monthly premiums 
that Medicare beneficiaries will pay.101 The MMA does not limit the premiums that will 
be charged to beneficiaries, instead requiring that PDPs and MA Plans negotiate prices 
with drug companies in creating their formularies, which in turn influence the price of 
premiums. Because the Part D drug benefit will be administered by private entities, and 
because of the uncertainties inherent in the new ASP calculation, the actual amount that 
will be reimbursed for covered drugs is not immediately apparent.102 What is evident, 
however, is that the MMA did not give the federal government the ability to control drug 
                                                 
96 See John D. Blum, Beyond the Bylaws: Hospital-Physician Relationships, Economics, and Conflicting 
Agendas, 53 BUFF. L. REV., 459, 463 (2005) (“hospitals, as a result of PPS, were motivated to introduce 
operational efficiencies”); Crimm, supra note 94, at 22 – 27 (discussing the rise of managed care and cost 
containment in the 1980s); E. Haavi Morreim, Cost Containment and the Standard of Medical Care, 75 
CAL. L. REV. 1719, 1720–21 (1987) (discussing how in the 1980s commercial insurers began to limit 
reimbursements in response to escalating healthcare costs). 
97 See STARR, supra note 85, at 398 – 404; Rand E. Rosenblatt, The Four Ages of Health Law, 14 
HEALTH MATRIX 155, 177- 90 (2004). 
98 The same arguably could be said of physicians, who had managed care imposed on them by the Health 
Maintenance Organization Act of 1973, Pub. L. No. 93-222, § 2, 87 Stat. 914, 931 (1973) (current version 
at 42 U.S.C. § 30e-10 (2006)). See STARR, supra note 85, at 299 – 306 (tracing the early history of the 
AMA’s resistance to health insurance of any kind). 
99 See generally Crimm, supra note 92, at 17 – 22 & nn. 56 – 74. 
100 See Robert Pear, Health Costs Will Keep Rising, U.S. Says, Along with Government Share of Paying 
Them, N.Y. TIMES, Feb. 24, 2005, at A20. The article stated, “Medicare, which now accounts for 2 
percent of spending on prescription drugs, will account for 28 percent next year.” Id. Cf. Alex Berenson, 
Medical Journal Criticizes Merck Over Vioxx Data, N.Y. TIMES, Dec. 9, 2005, at A1 (describing the 
unusual attack in the New England Journal of Medicine on Merck and its alleged misrepresentation of 
clinical trial results); Kevin Hassett, The Misguided Assault on the U.S. Drug Industry, BLOOMBERG, 
Aug. 29, 2005, available at tinyurl.com/ebuta (last visited May 24, 2007) (the U.S. drug industry is under 
an “assault”). These trends are furthered by Democrats’ efforts to facilitate centralized drug price 
negotiations. 
101 See MMA, Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2071. 
102 See id. § 303, 117 Stat. 2233. 
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prices under Part D (a fact that may change if the new Democratic majority is successful 
with its agenda). 
 
The Medicare Part D system appears to be similar to the original indemnity model that 
was used for hospitals under Part A, under which system the price was set by the 
healthcare provider with virtually no direct control by the reimbursing government 
agency.103 Such a laissez-faire approach may not be inherently improper, but it has 
historically been disfavored and seems unlikely to achieve longevity. Also, it does not 
appear to be consistent with Medicaid drug reimbursement methodology, which has 
required a measurable discount from pharmaceutical manufacturers. Learning from the 
lessons of hospitals, which had insisted (in a manner similar to the current pharmaceutical 
industry) that profit was necessary for ongoing growth and that constraints should not be 
enacted, the pharmaceutical industry may wish to consider what form of cost containment 
it prefers. If the industry can formulate its own constraints, then it may avoid the 
imposition of an arduous system similar to the IPPS. 
 
Given past experiences, it seems logical to anticipate that where federal money exists in 
unrestricted amounts, increased provision of items and services will follow.104 Where 
increased provision of items and services occur, fraud and abuse (and thus prosecution) 
may also arise.105 The current state of virtually un-conditional payment for Part D drugs 
brings the pharmaceutical industry full circle in terms of compliance concerns and 
presents yet more evidence to anticipate enhanced governmental scrutiny. Congress and 
the OIG have stated that, due to the amount of money being spent on Part D services, 
they are vigilant for fraud in the new drug program.106 This kind of scrutiny with regard 
                                                 
103 See Jacqueline Fox, Medicare Should, but Cannot, Consider Cost: Legal Impediments to a Sound 
Policy, 53 BUFF. L. REV. 577, 631 – 32 (2005) (noting that Medicare has trouble setting limits on 
treatments based solely on cost, but that it manages to control cost through other methods that are less 
straightforward and less sound). 
104 See Jill R. Horwitz, Making Profits and Providing Care: Comparing Nonprofit, For-Profit and 
Government Hospitals, 24 HEALTH AFF. 790 at 793 – 94 (2005) (describing the increase in certain 
hospital services that follows increases in Medicare reimbursement and the decreased provision of services 
that follows cost-cutting by Medicare). 
105 See Elizabeth A. Weeks, Gauging the Cost of Loopholes: Health Care Pricing and Medicare Regulation 
in the Post-Enron Era, 40 WAKE FOREST L. REV. 1215, 1226–42 (2005) (using Tenet as an example of 
a healthcare provider that seized the opportunity for unlimited funding based on a Medicare policies 
regarding outliers and that ultimately was investigated and prosecuted due to its high costs and aggressive 
billing). The author proceeds to note that Medicare Part D contains an “open invitation for pricing abuses.” 
Id. at 1261. 
106 Recent announcements regarding drug industry fraud often seem to be accompanied by statements to 
this effect. To wit: 
 
Spokesmen for Caremark, Medco and Express Scripts say they already disclose the 
payments they receive from drug companies as the pharmacy benefit managers select 
certain drugs for preferred status, which translates into larger sales. With the Medicare 
drug benefit, Congress has asked federal officials to make sure that such practices do not 
result in increased costs to the program. 
 
Milt Freudenheim, Caremark to Settle Whistle-Blower Suit, N.Y. TIMES, Sept. 9, 2005, at C14 (emphasis 
added). 
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to costs and levels of reimbursement often is followed by stepped-up fraud and abuse 
prosecution to recoup illicitly gained federal money. 
 
VII. Conclusion 
 
The pharmaceutical industry, somewhat suddenly, finds itself at the center of many 
different statutory and regulatory schemes, sources of authority, societal developments, 
and intensified scrutiny.107 Viewed together, these disparate elements illuminate a need 
for extra caution on the part of the industry, at least in the form of compliance programs 
that expand beyond the existing letter of the law—compliance programs as originally 
envisioned simply may not suffice. Without more stringent self-regulation, the intense 
interest in the pharmaceutical industry may lead to a regulatory push that could eliminate 
extant uncertainty but also result in unanticipated and cumbersome measures for the 
industry. 
                                                 
107 E.g., Stephanie Saul, In the Newest War of the States, Forget Red and Blue, These Battle Lines are 
Forming Over Rapidly Rising Drug Prices, N.Y. Times, Jan. 31, 2006, at C1 (describing the number of 
states that are attempting to lower pharmaceutical expenses and the lobbying effort in each state by the 
pharmaceutical industry). 
